How the TechBio UK stage leads to conversations with pharma: Scripta’s story
Peter Hamley, Founder and CEO of Scripta Therapeutics, presenting at TechBio UK
Taking to the stage at TechBio UK gives members a chance to share their science with potential partners. For Scripta Therapeutics, conversations continued beyond the conference, with big pharma meetings lined up around Jefferies and BIO-Europe.
Scripta is proud to have been members of BIA since we started 18 months ago. We are grateful for the opportunities BIA has given us, such as inclusion in the TechBio report and the recent TechBio UK symposium, which led to several fruitful conversations with pharma companies. As we grow our disease-agnostic drug discovery platform, we are looking forward to continuing to benefit from BIA’s support.
Sharing the science behind Scripta
Selected to present in the therapeutics track, Scripta won best-in-track with a platform leveraging transcription factor biology and proprietary AI to uncover novel biology.
Transcription factors help determine which genes a cell switches on or off. Scripta starts with genome-wide mapping of the transcription factors defining and driving disease. It then identifies and predicts molecules and targets that modulate them.
Validating the results in Scripta’s pre-mapped, patient-derived models closes the loop.
Working with disease models developed with co-founder Professor Noel Buckley at the University of Oxford, the team is focusing initially on neurodegenerative diseases such as Alzheimer’s, Parkinson’s and ALS.
The team mentioned at TechBio UK that transcription factors are implicated across the vast majority, if not all, human diseases. Its validated approach is highly partnerable, both in neurodegeneration and other indications.
At the conference, Scripta reported it has achieved neurodegeneration proof of concept of disease modification in around 18 months.
The team sees partnering opportunities across neurodegeneration and other indications, exploiting the role transcription factors play in many diseases.
Keeping the conversation going
Dr Peter Hamley, CEO and Founder of Scripta, found presenting on the main stage sparked promising follow-up discussions, including a planned meeting with a pharma companies at BIO-Europe and Jefferies.
Scripta also featured in BIA’s TechBio report. Its case study gave potential partners or future investors a chance to explore the science behind the presentation.
For us at BIA, hearing where these connections lead is particularly rewarding. Scripta’s experience shows how sharing science can open doors.
Connecting members with investors and partners
TechBio UK brings members together with investors and pharma to explore shared interests. The showcase gives companies a platform to explain their progress directly to potential partners.
The TechBio Investor Breakfast Club offers investors space to discuss the sector in greater depth.
We encourage members to get involved and keep these conversations going as their science develops.
Explore Scripta’s story
Read Scripta Therapeutics: flipping the script on drug discovery in our TechBio report for a closer look at its platform.
Members can apply to join the TechBio community to grow their industry network and learn from each other.